A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022)
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 Listen to the podcast! In another record year for biopharma fundraisings, more money than ever
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 https://www.bioworld.com/ext/resources/Podcast-files/bioworld_ep12_061221_edit2.mp3?1639088948 In another record year for biopharma fundraisings, more money than ever pulsed through the
Harnessing the body’s natural killers to target cancer
Natural killer cells, the body’s first line of defence against emerging cancers, could be engineered into powerful, off-the-shelf cancer therapies. Natural killer (NK) cells are
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing
CEO Kleanthis Xanthopoulos touts the San Diego biotech’s engineering prowess in developing iPSC-derived NK cells and macrophages against cancerBy Alex Philippidis November 8, 2021 Shoreline
California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award
https://shorelinebio.com//wp-content/uploads/2021/11/CA-Life-Sciences-Pantheon-Awards-2021.mov Shoreline Biosciences, Inc. is thrilled and honored to be recognized by the California Life Sciences (CLS) as the #Pantheon2021 award winner for the Strategic Partnership of the Year Award.
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022)
SAN DIEGO, May 10, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, April 12, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022
San Diego, Calif., March 28, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)
Shoreline Biosciences Appoints Robert Hollingsworth, Ph.D., As Chief Scientific Officer
SAN DIEGO, March 15, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences to Present Multiple Posters on iPSC-Derived NK Cell Platform at AACR Annual Meeting 2022
San Diego, Calif., March 9, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires
San Diego, Calif., February 15, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)